Skip to content

Study of turmeric extract in prevention of uterine cervical cancer.

An open labelled clinical pilot study on safety and activity of Holistic extract of Haridra Curcuma longa Linn 600 mg extract capsule orally twice a day for 10 weeks for treatment of Low Grade Squammous Intraepithelial Lesions of Cervix (LSIL) in Pap smears in Women - HE-SIL

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/012184
Enrollment
25
Registered
2018-02-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Low-grade Squamous Inter-epithelial Lesions/ High-grade Squamous Intra-epithelial Lesions in Pap smears in women

Interventions

Intervention1: Holistic turmeric extract: Soft Gel Capsule of Holistic turmeric extract: 600 mg (Curcumin 200mg + Turmerone 200 mg + Polysaccharides 200 mg) Dosage: 1 capsule twice daily after breakfa

Sponsors

Pharmanza Herbals Pvt Ltd product supply and financial support
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Women between 30 and 65 years of age 2 Women with LSIL or HSIL reported in Pap smear and confirmed by colposcopy as LSIL 3 Willing to follow the protocol and give written consent 4 Using effective nonhormonal method of contraception- eg.Tubal ligation 5 Willing to abstain during treatment with antimicrobials if not treated earlier (or use of condoms)- However if they have been treated for PID within 4 weeks, they will not be given initial antimicrobial therapy as they are already treated 6 Women with controlled Diabetes or hypertension or thyroid therapy or other mineral or vitamin therapy will not be excluded if they have had a steady dosage for past 3 months. They will be advised to keep an interval of one and a half hour between their medication and the intake of holistic turmeric extract.

Exclusion criteria

Exclusion criteria: 1 Women with higher grades of abnormality in Pap smear, or colposcopy, suspected of cervical cancer. 2 Unexplained bleeding, heavy or irregular menstrual bleeding 3 Uncontrolled systemic diseases like hypertension, heart disease, diabetes, jaundice etc. 4 Women with organic gynec pathology- fibroids, prolapse, ovarian tumours. 5 Women with abnormal clinical biochemistry, hemoglobin below 9 gms %, LFT > 2 SD. 6 Positive VDRL or HIV tests. 7 Pregnancy and lactation within 6 months 8 Women with allergy to dietary component- turmeric, or any drugs to be used in the study.

Design outcomes

Primary

MeasureTime frame
Pap smear which does not progress to HSIL, or which may regress at 6 weeks and 10 weeks Colposcopy Not exceeding LSIL (cervical intraepithelial neoplasia Grade I) Timepoint: Pap smear at 6 weeks and 10 weeks Colposcopy at 6 weeks and 10 weeks

Secondary

MeasureTime frame
Serum IL-6 reductionTimepoint: 10 weeks

Countries

India

Contacts

Public ContactDr Jayashree Joshi

Medical Research Center of Kasturba Health Society

jayashreevjoshi@gmail.com02226246119

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026